Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA(R) (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer
Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA(R) (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer GlobeNewswire October 21, 2025 CAMBRIDGE, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) — Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to […]